Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of “Hold” by Brokerages

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been given an average rating of “Hold” by the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $21.67.

A number of research analysts have commented on the company. ValuEngine cut Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.

In other news, CEO Richard A. Md Miller purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $10.79 per share, for a total transaction of $107,900.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 46.40% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in CRVS. New York State Common Retirement Fund lifted its stake in Corvus Pharmaceuticals by 2,269.1% during the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock worth $115,000 after purchasing an additional 9,099 shares in the last quarter. SG Americas Securities LLC acquired a new position in Corvus Pharmaceuticals during the fourth quarter worth $150,000. Alliancebernstein L.P. acquired a new position in Corvus Pharmaceuticals during the second quarter worth $175,000. California State Teachers Retirement System lifted its stake in Corvus Pharmaceuticals by 121.2% during the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock worth $181,000 after purchasing an additional 8,200 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in Corvus Pharmaceuticals by 338.4% during the second quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock worth $188,000 after purchasing an additional 12,017 shares in the last quarter. Institutional investors own 83.37% of the company’s stock.

Corvus Pharmaceuticals (NASDAQ:CRVS) opened at $8.24 on Friday. Corvus Pharmaceuticals has a twelve month low of $8.00 and a twelve month high of $22.14. The company has a market capitalization of $195.05, a P/E ratio of -3.06 and a beta of -1.51.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. research analysts expect that Corvus Pharmaceuticals will post -2.82 EPS for the current fiscal year.

WARNING: “Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of “Hold” by Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/corvus-pharmaceuticals-inc-crvs-given-average-recommendation-of-hold-by-brokerages.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply